Doubts over UK research head

Parliamentary committee questions MRC chair's leadership

Written byStephen Pincock
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
An influential British parliamentary committee has expressed serious doubts about the suitability of John Chisholm, chair of the Medical Research Council since last October, to lead the research agency.In an unusually scathing report released Tuesday, the House of Commons Select Committee on Science and Technology described Chisholm as "vague" and "evasive" and said that he showed "a lack of focus and clarity.""We had very serious doubts about whether Sir John is the right person to guide the MRC at such a critical time," Phil Willis, chair of the committee, told The Scientist. "It is now important that the government follows up on our report."The MRC is facing significant changes as it adapts to a new umbrella structure governing basic and clinical research, as well as coming to terms with new departmental structures brought in by new Prime Minister Gordon Brown. It will also soon appoint a new chief executive.The committee's role is to scrutinize science policy, a remit that includes assessing senior appointments made by the health minister. The 11-member committee interviewed Chisholm in late June. The report arising from that interview shows that Chisholm couldn't provide details of how he was recruited, saying at first that he was invited by Sir Keith O'Nions, the director-general of science and innovation, but later saying he was actually approached by a recruitment firm.
Later, when discussing the process of appointing consulting firm Ernst & Young to help with a review of the MRC's activities, he could not explain some details, such as how MRC staff and other stakeholders were consulted. The committee listed other areas where they considered his responses inadequate. "His explanation for the policy decision to increase contingency funding was unsatisfactory and he lacked the necessary knowledge to discuss the MRC's relationship with the other Research Councils," they said.Such a personal attack is an unusual move for the committee, said Peter Cotgreave from the Campaign for Science and Engineering. "One has to take it seriously," he told The Scientist. "They don't say that kind of thing gratuitously."Cotgreave said he didn't have anything against Chisholm, but acknowledged that the MRC is at a critical juncture. "It is going to be important that whoever is leading the MRC is completely on top of all the issues," he said.A spokeswoman for the MRC said the council would not be commenting immediately. "The government will make a response to the report and we will feed into that response," she said.Stephen Pincock mail@the-scientist.comLinks within this article:P. Hagan, "MRC unveils changes at the top," The Scientist May 11, 2007. http://www.the-scientist.com/news/display/53189/Select Committee on Science and Technology Eighth Report http://www.publications.parliament.uk/pa/cm200607/cmselect/cmsctech/746/74603.htm#a1
S. Pincock, "Protect basic research: UK scientists," The Scientist March 15, 2007. http://www.the-scientist.com/news/display/52939S. Pincock, "MRC head to step down," The Scientist March 8, 2006 http://www.the-scientist.com/article/display/15387
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform